Ayala Pharmaceuticals Inc (ADXS)

[mpreorder]

Here's the entire paragraph. It's under item 2.

ADXS-HER2 is an Lm –based antigen delivery product designed to target HER2 expressing solid tumors including human and canine osteosarcoma. The dose finding phase of the trial is complete. The Company has evaluated the data and decided not to proceed to the expansion phase of the trial. In addition, based on the Company’s priorities, the ADXS-HER2 development program, which includes Pediatric Osteosarcoma, will be discontinued but remains open to investigator-initiated research or licensing proposals.

Emphasis mine. All trials with HER2 were halted. I'm not sure how many there were. When I have time I'll check clinicaltrials.gov and get back to you.